Journal
BLOOD REVIEWS
Volume 31, Issue 2, Pages 43-62Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2016.09.005
Keywords
AML; Older adults; Treatment; Induction chemotherapy; Clinical trial
Categories
Funding
- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)
Ask authors/readers for more resources
More than half of the patients with acute myeloid leukaemia (AML) are older than 60 years. The treatment outcomes in this group remain poor with a median overall survival of <1 year. Selecting initial treatment for these patients involves an assessment of 'fitness' for induction chemotherapy. This is done based on patient and disease-related characteristics which help to estimate treatment-related mortality and chance of complete remission with induction chemotherapy. If the risk of treatment-related mortality is high and/or the likelihood of a patient achieving a complete remission is low, lower-intensity treatment (low-dose cytarabine, decitabine and azacitidine) should be discussed. As outcomes in both groups of patients remain poor, enrolment into clinical trials of novel agents with varying mechanisms of action should be considered for all older adults with AML. Novel agents in Phase III development include CPX-351, guadecitabine (SGI-110), quizartinib, crenolanib, sapacitabine, vosaroxin and volasertib. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available